国家神经系统疾病临床医学研究中心数据管理与共享系统

Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases

《国家中心数据管理与共享系统操作说明书 —— 研究者部分》

Aminotransferase Level and the Effects of Dual Antiplatelet in Minor Stroke or Transient Ischemic Attack: A post hoc Analysis of a Randomized Control Trial

第一作者：Suo, yue

通讯作者：Wang, yongjun

Alanine aminotransferase Aspartate aminotransferase Recurrent stroke Minor ischemic stroke Transient ischemic attack

基本信息

  • 负责人：Suo, yue
  • 数据来源： CHANCE
  • 论文编号：CHANCE20190263
  • 发表时间：2022-12-09

2022-12-09

已发表文章

发表杂志：Cerebrovascular Diseases

发表类型: Original Contributions

影响因子(IF): 3.104

PMID: 36502795 Pubmed原文链接 全文下载

主要研究背景及目的

Objectives of this study include:1)Compare the 3-month recurrence, death, dependency between subgroups of different level of de ritis ratio(AST/ALT), AST, ALT; 2)Evaluate the efficacy of dual antiplatelet vs single antiplatelet therapy in minor stroke and TIA in different subgroups according to level of de ritis ratio/abnormal liver function; 3)Investigate the influence of correlation between de ritis ratio/abnormal liver function（elevated transmerase） and CYP2C19 loss-of-function allele on effect of dual antiplatelet therapy.

方法

We will present the categorical variables as proportions, continuous variables as mean and SD. In the univariate analysis, Kruskal-Wallis test was used for comparisons of skewed continuous variables and ordinal variable. Categorical variables were compared with the x2 statistics or Fisher exact test as appropriate. Cox proportional hazard regression model and logistic regression model will be used to analyze the association of abnormal liver funcition and stroke recurrence. Stratified analysis by De ritis ratio, level of ALT, AST and CYP2C19 loss-of-function carrier status will also be performed. A two-sided P value of less than 0.05 will be considered to reach statistical significance. All statistical analyses will be performed by using SAS version 9.4 software (SAS Institute Inc., Cary, NC, USA).

结论

Dual antiplatelet treatment was safe for minor stroke or high-risk TIA patients with mildly elevated aminotransferase. Mild elevation of ALT or AST did not undermine the protective efficacy of the dual antiplatelet regimen in reducing recurrent stroke or TIA within 90 days after MIS or TIA. The interaction between the CYP2C19 loss-of-function allele carrier status and aminotransferase level on the efficacy of dual antiplatelet treatment was not observed.

主要结果